Home » Stocks » DRNA

Dicerna Pharmaceuticals, Inc. (DRNA)

Stock Price: $27.61 USD 1.55 (5.95%)
Updated May 18, 2021 1:37 PM EDT - Market open
Market Cap 2.00B
Revenue (ttm) 177.88M
Net Income (ttm) -120.22M
Shares Out 76.26M
EPS (ttm) -1.60
PE Ratio n/a
Forward PE 28.49
Dividend n/a
Dividend Yield n/a
Trading Day May 18
Last Price $27.61
Previous Close $26.06
Change ($) 1.55
Change (%) 5.95%
Day's Open 26.39
Day's Range 26.24 - 28.00
Day's Volume 817,563
52-Week Range 16.50 - 32.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -39.29% and -20.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today reported its financial results for the first quarter ended March 31, 2021 and provided a corporate update.

1 week ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that the Company will release its first quarter 2021 financial results after market close on Thursday, May 6, 2021.

2 weeks ago - Business Wire

Royalty Pharma plc (NASDAQ: RPRX) has acquired  Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) royalty interest in Oxlumo (lumasiran) for an upfront cash payment of $180 million and up to $60 million in c...

Other stocks mentioned: RPRX
1 month ago - Benzinga

LEXINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Dicerna today announced that Royalty Pharma has acquired Dicerna's royalty interest in OXLUMO™ (lumasiran) for up to $240 million.

Other stocks mentioned: RPRX
1 month ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options for one new employee

1 month ago - Business Wire

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) has announced new data from preclinical studies of its GalXC-Plus RNAi technology demonstrating its potential to deliver messenger RNA (mRNA) knockdown against...

1 month ago - Benzinga

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced new data from preclinical studies of its GalXC-Plus RNAi technology within the central nervous system (CNS) at the OPT Congress.

1 month ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna will present new nonclinical data discussing the Company's GalXC-Plus™ RNAi technology as part of the OPT Virtual Congress, March 30-31, 2021.

1 month ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna will host a webinar on its alcohol use disorder (AUD) candidate, DCR-AUD. The event will take place on March 18, 2021 at 4:30 p.m. ET.

2 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today announced that Roche has initiated RG6346 in the Roche sponsored Phase 2 combination trial for the treatment of chronic HBV infection.

2 months ago - Business Wire

With the trading day more than halfway over, the broad markets pulled back from their impressive start to the week.

Other stocks mentioned: CCL, RCL, BMO, FOLD, GLNG, SWCH, TRUE
2 months ago - 24/7 Wall Street

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today reported its financial results for the full year ended Dec. 31, 2020 and provided a corporate update.

2 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences.

2 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna will release its fourth quarter and full year 2020 financial results after market close on Thursday, Feb. 25, 2021.

3 months ago - Business Wire

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) initiates patient dosing in Phase 1 PHYOX 4 trial evaluating its lead candidate, nedosiran, to treat primary hyperoxaluria, a rare condition characterized by t...

3 months ago - Benzinga

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced initiation of patient dosing in its PHYOX™4 clinical trial to assess nedosiran for the treatment of primary hyperoxaluria type 3.

3 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that Doug Fambrough will participate in two events at the H.C. Wainwright Virtual BioConnect Conference taking place Jan. 11-14.

4 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that Novo Nordisk has nominated its first candidate for development under the existing agreement between the two companies.

4 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced the Company approved the grant of inducement stock options of common stock and restricted stock units among three new employees.

4 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today announced the enrollment completion of the PHYOX™2 pivotal trial of nedosiran for the treatment of primary hyperoxaluria.

4 months ago - Business Wire

Investors need to pay close attention to Dicerna (DRNA) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Dicerna is right behind Alnylam in the RNAi space. Its lead candidate is nedosiran targeting primary hyperoxaluria.

5 months ago - Seeking Alpha

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among six new employees.

5 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced positive updated Phase 1 data on its investigational GalXC™ RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV).

6 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced FDA acceptance of the IND Application filed by Lilly for LY3561774, clinical-stage candidate to emerge from their collaboration.

6 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that Douglas M. Fambrough, Ph.D., president and CEO, will be participating in fireside chats at two upcoming investor conferences.

6 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna will present an update on the Company's early-stage development of extrahepatic RNAi therapeutics at TIDES Europe 2020.

6 months ago - Business Wire

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and o...

6 months ago - Insider Monkey

Dicerna Pharmaceuticals, Inc. (DRNA) CEO Doug Fambrough on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today reported its financial results for the third quarter ended Sep. 30, 2020.

6 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among nine new employees.

6 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna will present updated data related to RG6346, an RNAi investigational therapy, at The Liver Meeting® Digital Experience™ 2020.

6 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that it will release its Q3 2020 financial results and will provide a general business update on Thursday, Nov. 5.

6 months ago - Business Wire

Dicerna Pharmaceuticals (DRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry expertise in ...

Other stocks mentioned: BPMC, ANAB, QURE, SPRO
6 months ago - Insider Monkey

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced positive new interim data from its ongoing PHYOX3 open-label trial of nedosiran, an investigational therapy for PH1, PH2 and PH3.

6 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that Doug Fambrough will participate in a virtual fireside chat at the H.C. Wainwright HBV Mini-Conference on Tuesday, Oct. 20.

7 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that clinical data on nedosiran, an investigational candidate for the treatment of PH, will be presented at ASN Kidney Week 2020.

7 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M....

7 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced the hiring of Ling Zeng, Esq.

8 months ago - Business Wire

Dicerna develops RNAi therapies. Several large-cap pharma companies are collaborators.

8 months ago - Seeking Alpha

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that the Company will be participating in four virtual investor conferences in September.

8 months ago - Business Wire

Dicerna Pharmaceuticals, Inc. (DRNA) CEO Douglas Fambrough on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -304.76% and -46.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna presents positive clinical data for investigational treatments RG6346 for chronic HBV and Nedosiran for PH and preclinical data in new tissues

9 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today reported its financial results for the second quarter ended June 30, 2020.

9 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced the appointment of Shreeram Aradhye, M.D.

9 months ago - Business Wire

Dicerna Pharmaceuticals (DRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that it will release its Q2 2020 financial results before market open on Thurs.

9 months ago - Business Wire

About DRNA

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the... [Read more...]

Industry
Biotechnology
IPO Date
Jan 30, 2014
CEO
Douglas Fambrough
Employees
302
Stock Exchange
NASDAQ
Ticker Symbol
DRNA
Full Company Profile

Financial Performance

In 2020, DRNA's revenue was $164.31 million, an increase of 587.36% compared to the previous year's $23.90 million. Losses were -$112.75 million, -6.40% less than in 2019.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for DRNA stock is "Strong Buy." The 12-month stock price forecast is 39.67, which is an increase of 43.68% from the latest price.

Price Target
$39.67
(43.68% upside)
Analyst Consensus: Strong Buy